ILUMYA® (tildrakizumab-asmn) Found Effective for Treatment of Moderate-to-Severe Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference

Data Presented at American Academy of Dermatology Shows Significant Improvement in Moderate-to-Severe Nail Psoriasis with No New Safety Signals PRINCETON, N.J., March 7, 2025 /PRNewswire/ — Sun Pharmaceutical Industries, Inc., USA, a wholly owned subsidiary of Sun Pharmaceutical…